Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 4Thyroid Carcinoma, Anaplastic 3Neoplasms 3Glioma 3Recurrence 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Thyroid Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Refractory Differentiated Thyroid Gland Carcinoma 1Rare Malignant Neoplasm 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Dexamethasone 5Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2ponatinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia × trametinib × Clear all
NCT05658640 2025-09-16

HEM-iSMART D

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡